Literature DB >> 36186230

Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases.

Masayuki Inoue1, Ayako Kimura1, Tomomi Oka1, Aya Yajima1, Yudai Higuchi1, Tatsuki Endo1, Hideki Watanabe1, Hiroshi Nakagomi1, Toshio Oyama2.   

Abstract

Neo-adjuvant chemotherapy (NAC) has become a standard treatment for advanced breast cancer because of the advantage of monitoring drug sensitivity and enabling breast-conserving therapy. The changes during NAC are also important to know the biological characteristics of the tumor. We experienced two cases with cystic degeneration and enhancement of the cyst wall during NAC for triple negative breast cancer (TNBC). They were diagnosed to have breast cancer with squamous metaplasia. In case 1, a 37-year-old woman with right breast cancer diagnosed as TNBC, T3N3M0, Stage 3b was treated with NAC. MRI showed a cystic degeneration with a diameter of 3.5 cm and enhancement of the cyst wall, and the other nodules were extinguished. The histopathological finding of the surgical specimen revealed solid tubular carcinoma with squamous metaplasia. In case 2, a 58-year-old woman with right breast cancer diagnosed as HER2 enriched subtype, T2N0M0 stage 2 was treated with NAC containing trastuzumab. The post-NAC MRI showed extinguishment of the mass in the right breast, but showed a cystic lesion with 24 mm in diameter and enhancement of its wall in the left breast. She underwent breast conserving surgery for bilateral breast cancer, and histopathological finding of the surgical specimen indicated complete remission of right breast cancer and squamous cell carcinoma developed in the left breast. These changes are impressive and remind us that there are metaplastic changes (especially for squamous metaplasia) with resistance to chemotherapy.
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.

Entities:  

Keywords:  Cystic degeneration; Neo-adjuvant chemotherapy; Squamous cell carcinoma; Triple negative breast cancer

Year:  2022        PMID: 36186230      PMCID: PMC9522963          DOI: 10.1007/s13691-022-00553-y

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  15 in total

Review 1.  Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.

Authors:  Nobue Kumaki; Shinobu Umemura; Xiaoyan Tang; Yuki Saito; Yasuhiro Suzuki; Yutaka Tokuda
Journal:  Breast Cancer       Date:  2011-02-03       Impact factor: 4.239

2.  Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base.

Authors:  Christopher M Pezzi; Lina Patel-Parekh; Karin Cole; Jan Franko; V Suzanne Klimberg; Kirby Bland
Journal:  Ann Surg Oncol       Date:  2006-10-26       Impact factor: 5.344

3.  Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome.

Authors:  K A Behranwala; N Nasiri; N Abdullah; P A Trott; G P H Gui
Journal:  Eur J Surg Oncol       Date:  2003-05       Impact factor: 4.424

4.  Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy.

Authors:  Lori R Arlinghaus; Xia Li; Mia Levy; David Smith; E Brian Welch; John C Gore; Thomas E Yankeelov
Journal:  J Oncol       Date:  2010-09-29       Impact factor: 4.375

Review 5.  Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).

Authors:  Abeer H Abdelhafez; Benjamin C Musall; Wei T Yang; Gaiane M Rauch; Beatriz E Adrada; KennethR Hess; Jong Bum Son; Ken-Pin Hwang; Rosalind P Candelaria; Lumarie Santiago; Gary J Whitman; Huong T Le-Petross; Tanya W Moseley; Elsa Arribas; Deanna L Lane; Marion E Scoggins; Jessica W T Leung; Hagar S Mahmoud; Jason B White; Elizabeth E Ravenberg; Jennifer K Litton; Vicente Valero; Peng Wei; Alastair M Thompson; Stacy L Moulder; Mark D Pagel; Jingfei Ma
Journal:  Breast Cancer Res Treat       Date:  2020-09-13       Impact factor: 4.872

6.  Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.

Authors:  A Fangberget; L B Nilsen; K H Hole; M M Holmen; O Engebraaten; B Naume; H-J Smith; D R Olsen; T Seierstad
Journal:  Eur Radiol       Date:  2010-12-03       Impact factor: 5.315

Review 7.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

8.  Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma.

Authors:  Willard Wong; Edi Brogi; Jorge S Reis-Filho; George Plitas; Mark Robson; Larry Norton; Monica Morrow; Hannah Y Wen
Journal:  NPJ Breast Cancer       Date:  2021-07-22

9.  Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: A case report.

Authors:  Jian Zhu; Kainan Li; Xuefeng Dong; Peng Zhou; Peifeng Li; Jingwang Bi
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 10.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Authors: 
Journal:  Lancet Oncol       Date:  2017-12-11       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.